NCT02676310View on ClinicalTrials.gov

Safety, Tolerability, and Pharmacokinetics of Bimatoprost in Men With Androgenetic Alopecia (AGA)

PHASE1TerminatedINTERVENTIONAL
Enrollment

53

Participants

Timeline

Start Date

March 31, 2016

Primary Completion Date

January 31, 2017

Study Completion Date

March 31, 2017

Conditions
AlopeciaAlopecia, AndrogeneticBaldness
Interventions
DRUG

Bimatoprost

Trial Locations (3)

24501

E&R Research Foundation, Lynchburg

77845

J&S Studies Inc., College Station

78759

DermResearch, LLC, Austin

Sponsors

Lead Sponsor

Allergan
All Listed Sponsors
lead

Allergan

INDUSTRY

NCT02676310 - Safety, Tolerability, and Pharmacokinetics of Bimatoprost in Men With Androgenetic Alopecia (AGA) | Biotech Hunter | Biotech Hunter